Argenx buys Forte's FB102.
Argenx agrees to acquire Forte Biosciences for $2.2 billion, expanding immunology pipeline with FB102.
Anonymous
Key Points
1
Argenx paid an 86% premium to Forte’s volume-weighted average price since July 9 and about 41% above Forte’s July 24 close, underscoring a strong valuation tied to FB102’s potential.
2
Argenx previously participated in Forte’s $150 million public offering on April 8, disclosed in regulatory filings, providing an early view into FB102 before pursuing the full acquisition.
3
FB102 is a first-in-class anti-CD122 antibody that blocks IL-2 and IL-15–driven T- and NK-cell activation while preserving regulatory T cells, with mechanism and early signals explained—mirroring broad potential across autoimmune diseases.
4
In a 43-patient Phase 1b vitiligo trial, FB102 showed a 29.6% mean improvement in facial repigmentation at Week 24 versus 7.9% for placebo, with adverse events mild to moderate and effects persisting for weeks after treatment ended.
Argenx SE has agreed to buy US biotech Forte Biosciences for roughly $2.2 billion in cash, paying $77 per share — a 41% premium to Forte's July 24 closing price, according to TipRanks. Both company boards approved the deal, which is expected to close in the third quarter of 2026 via a cash tender offer followed by a merger.
Forte shares jumped 39% in premarket trading after the announcement, according to MarketScreener. Argenx will fund the entire deal from cash on hand, adding Forte's lead drug, FB102, to its immunology portfolio.
86% Premium Signals Argenx's Confidence in FB102
Argenx is paying an 86% premium to Forte's volume-weighted average price since July 9, according to TipRanks. That steep markup reflects how highly Argenx values FB102, Forte's lead antibody drug. The deal structure is straightforward: shareholders tender their shares at $77 each, then Forte becomes a wholly owned subsidiary of Argenx.
Argenx was not a stranger to Forte before this deal. The company joined Forte's $150 million public offering on April 8, according to Pharmaphorum. That early investment gave Argenx an inside look at FB102's potential before it moved to buy the whole company.
FB102: A First-in-Class Drug That Targets Multiple Diseases
FB102 is an anti-CD122 antibody — a drug that blocks two key immune signals called IL-2 and IL-15. These signals drive overactive T cells and NK cells, which attack the body in autoimmune diseases. Importantly, FB102 leaves regulatory T cells intact. Those are the immune cells that keep inflammation in check.
Argenx calls FB102 a "pipeline in a product," according to Endpoints News. That means one drug could work across many diseases. Targets include vitiligo, celiac disease, and alopecia areata — a condition that causes hair loss. This gives Argenx a major growth path beyond its current top seller, Vyvgart.
Phase 1b Vitiligo Trial Shows Promising Early Results
In a 43-patient Phase 1b trial in vitiligo patients, FB102 showed strong early signals. Patients taking FB102 saw a 29.6% mean improvement in facial repigmentation at Week 24. The placebo group improved by just 7.9% over the same period. Side effects were mild to moderate, and benefits lasted weeks after treatment ended.
Vitiligo is a skin condition where patches of skin lose their color. The trial results suggest FB102 can help the skin regain pigment by calming the immune attack causing the damage. These results helped convince Argenx that FB102 is worth a $2.2 billion bet, according to Pharmaphorum.
Deal Diversifies Argenx Beyond Its Blockbuster Drug Vyvgart
Argenx built its reputation on Vyvgart, a drug for rare autoimmune nerve diseases. Vyvgart has been a strong revenue driver, but Argenx has been looking for ways to grow its pipeline. The Forte deal gives it a new lead asset with a different mechanism targeting a broader set of diseases, according to TradingView.
The acquisition is subject to a majority of Forte shares being tendered and other standard closing conditions. If those conditions are met, Argenx expects to wrap up the deal in Q3 2026. The move positions Argenx as a broader immunology company, not just a one-drug story.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
22
Articles
110
Reach
132
A
AnonymousAuthor
